Novartis Ag (NVSEF) Operating Expenses (2009 - 2025)

Novartis Ag (NVSEF) has 15 years of Operating Expenses data on file, last reported at -$6.2 billion in Q2 2025.

• Quarterly Operating Expenses fell 13.03% year-over-year to -$6.2 billion in Q2 2025, while the trailing twelve-month figure through Mar 2026 was -$6.2 billion (up 61.87% YoY) and the FY2025 annual result came in at $24.4 billion, up 8.23% from the prior year.
• Operating Expenses improved to -$6.2 billion in Q2 2025 per NVSEF's latest filing, from -$10.7 billion in the prior quarter.
• The five-year high for Operating Expenses was -$672.0 million in Q3 2022, with the low at -$10.9 billion in Q4 2023.
• Average Operating Expenses over 5 years is -$4.0 billion, with a median of -$3.1 billion recorded in 2021.
• The widest YoY moves for Operating Expenses: up 11.25% in 2023, down 1273.07% in 2023.
• Novartis Ag's Operating Expenses stood at -$808.0 million in 2021, then increased by 2.1% to -$791.0 million in 2022, then tumbled by 1273.07% to -$10.9 billion in 2023, then climbed by 1.31% to -$10.7 billion in 2024, then soared by 42.45% to -$6.2 billion in 2025.
• Business Quant data shows NVSEF's Operating Expenses at -$6.2 billion in Q2 2025, -$10.7 billion in Q4 2024, and -$5.5 billion in Q2 2024.